Aktis Oncology to Present at Upcoming March Investor Conferences

Company Overview - Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing technologies [4] - The company's most advanced program, AKY-1189, targets Nectin-4 and has multi-indication potential across various tumor types, including locally advanced or metastatic urothelial cancer, breast cancer, non-small cell lung cancer, colorectal cancer, cervical cancer, and head and neck cancer [4] - Aktis' second pipeline program, AKY-2519, targets B7-H3 expressing tumors, including prostate and lung cancers [4] Technology and Innovation - Aktis has developed a proprietary, isotope-agnostic miniprotein radioconjugate platform designed to selectively deliver the tumor-killing properties of radioisotopes to targeted tumors [3] - The therapeutic miniprotein radioconjugates maximize anti-cancer activity through high penetration, internalization, and retention in cancer cells while clearing quickly from normal organs and tissues [3] - The platform allows clinicians to visualize and verify target engagement with imaging isotopes prior to exposure to therapeutic radioisotopes, addressing unmet needs in solid tumors [3] Upcoming Events - Matthew Roden, Ph.D., President and CEO of Aktis Oncology, will present at the TD Cowen 46 Annual Health Care Conference on March 3, 2026, at 1:10 p.m. ET in Boston, MA [2] - He will also present at the Leerink Partners Global Healthcare Conference on March 9, 2026, at 1:40 p.m. ET in Miami, FL [2] - A live webcast of the presentations will be available on the Investors section of the Aktis website, with an archived replay accessible for approximately 90 days [2]